PD-1 inhibitors after hedgehog inhibitors stop working or aren't tolerated
Bring a printable list of questions to your appointment, or share this page with someone who needs it.
Most basal cell carcinomas (BCCs) never need anything more than a single office procedure. A small number grow deep, come back after surgery or radiation, or spread — and these advanced tumors are treated with medication that works throughout the body. The usual first choice is a hedgehog pathway inhibitor (vismodegib or sonidegib).
Immunotherapy is the next step when a hedgehog inhibitor is no longer an option. This article explains what immunotherapy for BCC is, exactly when doctors turn to it, how well it works, and what living with it involves.
The immune system normally keeps its T cells from attacking the body's own tissue by using "checkpoint" switches. One of these switches is a protein called PD-1. Some cancers exploit it to hide from the immune system.
The immunotherapy approved for advanced BCC is cemiplimab (brand name Libtayo), a PD-1 inhibitor, also called a checkpoint inhibitor. It blocks the PD-1 switch so that T cells can recognize and attack the tumor. It is given as an intravenous (IV) infusion, usually every three weeks.
BCCs carry a very high number of DNA mutations from years of ultraviolet damage, which makes them look "foreign" to the immune system once the brakes are released. That biology is the rationale for trying checkpoint immunotherapy in this disease.
Immunotherapy is a second-line treatment for advanced BCC. It is considered when the disease is locally advanced or metastatic, surgery and radiation are no longer reasonable options, and one of the following is true:
The tumor grew or spread again while the patient was taking vismodegib or sonidegib. Over time many BCCs become resistant to hedgehog blockade, and switching to a drug with a completely different mechanism can regain control.
Some tumors do not shrink at all on a hedgehog inhibitor. If there is no meaningful response after roughly nine months, doctors generally consider that treatment a failure and move on.
Muscle cramps, taste loss, hair thinning, and fatigue lead a large share of patients to stop hedgehog inhibitors even when the drug is helping. If dose adjustments and treatment breaks are not enough, immunotherapy becomes the alternative.
Immunotherapy can also be an option for people who cannot safely start a hedgehog inhibitor in the first place. The decision is made by a team that typically includes a dermatologist, a medical oncologist, and a surgeon.
Cemiplimab was tested in a phase 2 trial (Study 1620) in patients whose advanced BCC had already progressed on or could not tolerate a hedgehog inhibitor:
About 31% of 84 patients had their tumor shrink significantly (an "objective response"), including 6% whose tumor disappeared on scans and exam.
In the metastatic group, roughly 22% of patients responded. Median overall survival in long-term follow-up was about 50 months.
Two points matter when reading these numbers. First, most patients do not have a major response — the majority see stable disease or continued growth. Second, when a response does happen it tends to be durable, often lasting well over a year, which is the main appeal of this approach compared with later lines of hedgehog therapy.
Responses can also be slow to appear, sometimes taking several months, so doctors usually continue treatment and repeat imaging before concluding it is not working.
Checkpoint immunotherapy has a different side-effect profile from hedgehog inhibitors. Many people tolerate it well, but the risks are real and are watched for closely.
Report new or worsening symptoms promptly. Most immune-related reactions are reversible when treated early, often with corticosteroids and by holding or stopping the drug. People with autoimmune disease or a prior organ transplant need an especially careful risk discussion.
If immunotherapy does not control the disease, options include returning to a hedgehog inhibitor, radiation to a specific problem area, or a clinical trial of a new drug or combination. Occasionally, medication shrinks a tumor enough that surgery becomes possible again.
Immunotherapy gives advanced BCC a genuine second line of systemic treatment. It is used when a hedgehog pathway inhibitor has failed, was never effective, or could not be tolerated, and the cancer still cannot be removed by surgery or radiation.
Only a minority of patients have a major response, but those responses can last a long time. Weighing that potential benefit against the risk of immune-related side effects is a conversation to have with a medical oncologist who treats skin cancer.
Disclaimer: This article is for educational purposes only and not a substitute for professional medical advice. Always consult a qualified dermatologist or oncologist about your personal diagnosis and treatment plan.
Chat with our AI guide for information about advanced basal cell carcinoma treatment
Chat with the Navigator